EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biomarin Pharmaceutical's enterprise value is $17,013 Mil.
Biomarin Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $2,419 Mil. Therefore, Biomarin Pharmaceutical's EV-to-Revenue for today is 7.03.
The historical rank and industry rank for Biomarin Pharmaceutical's EV-to-Revenue or its related term are showing as below:
BMRN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 6.54 Med: 11.19 Max: 27.8
Current: 7.03
During the past 13 years, the highest EV-to-Revenue of Biomarin Pharmaceutical was 27.80. The lowest was 6.54. And the median was 11.19.
BMRN's EV-to-Revenue is ranked better than 51.79% of 1031
companies
in the Biotechnology industry
Industry Median: 7.6
vs BMRN: 7.03
As of today (2024-04-23), Biomarin Pharmaceutical's stock price is $89.53.
Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $12.59. Therefore, Biomarin Pharmaceutical's PS Ratio for today is 7.11.
Biomarin Pharmaceutical EV-to-Revenue Historical Data
The historical data trend for Biomarin Pharmaceutical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Biomarin Pharmaceutical Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-Revenue
8.98
8.58
8.84
9.10
7.53
Biomarin Pharmaceutical Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-Revenue
9.10
8.37
7.26
7.20
7.53
Competitive Comparison
For the Biotechnology subindustry, Biomarin Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical EV-to-Revenue Distribution
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's EV-to-Revenue falls into.
Biomarin Pharmaceutical's current Enterprise Value is $17,013 Mil.
Biomarin Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,419 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical's share price for today is $89.53.
Biomarin Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 